ZLAB241115C22500
- 6.00
- 0.000.00%
Zai Lab Newsroom
U.S. stock market anomaly: zai lab surged 10% before the market opened and received a target price increase from jpmorgan.
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Analyst Ratings
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $38
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
Strong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel Optimism
Zaiding Pharmaceutical (09688.HK): KARXT has been approved for marketing by the FDA and will soon be submitted by the Chinese NDA
Morgan Stanley Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market Position
Zaiding Pharmaceutical (09688.HK): From outward to inner butterfly, global BIOPHARMA is on the rise
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Haitong Int'l: maintains a "outperform" rating on Zai Lab (09688) with a target price lowered to HKD 65.76.
Zaiding Pharmaceutical (09688.HK): Agamod raises sales guidelines, explosives potential
Zaiding Pharmaceutical (9688.HK): Agamod's annual revenue guidance raised to more than 80 million US dollars in anticipation of R&D catalysts
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
ZAI LAB LTD(9688.HK):EFGAR SALES GUIDANCE RAISED IN FY24E WHILE OVERALL MID-TERM PRODUCT SALES UNDER PRESSURE
Zai Lab Analyst Ratings
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)